Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
AM

AMRX

Market Closed

Amneal Pharmaceuticals, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & Generic
US
8.70K employees
CEO: Chirag K. Patel
Founded: 2018
$17.44
+$0.00(+NaN%)
Market Cap
5.57B
Beta
1.24
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Based on PERT weighted analysis (confidence: high), the fair value is $16.69, implying 5.6% downside from current levels. The stock appears fairly valued. Financial health scores indicate solid fundamentals (3.0/5). Monte Carlo analysis shows elevated downside risk (50% of scenarios below current price). Overall, this suggests a balanced risk/reward profile at current prices.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore AMRX

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

AMRX in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Drug Manufacturers - Specialty & Generic

Browse industry stocks →